Literature DB >> 29634945

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.

Vancheswaran Gopalakrishnan1, Beth A Helmink1, Christine N Spencer2, Alexandre Reuben1, Jennifer A Wargo3.   

Abstract

The microbiome is receiving significant attention given its influence on a host of human diseases including cancer. Its role in response to cancer treatment is becoming increasingly apparent, with evidence suggesting that modulating the gut microbiome may affect responses to numerous forms of cancer therapy. A working knowledge of the microbiome is vital as we move forward in this age of precision medicine, and an understanding of the microbiome's influence on immune responses and cancer is key. It is also important to understand factors influencing the gut microbiome and strategies to manipulate the microbiome to augment therapeutic responses.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; cancer immunosurveillance; gut microbiome; immunity; immunotherapy; immunotherapy response; immunotherapy toxicity; microbiome; microbiome manipulation; microbiota

Mesh:

Year:  2018        PMID: 29634945      PMCID: PMC6529202          DOI: 10.1016/j.ccell.2018.03.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  305 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori.

Authors:  Yanqiang Huang; Xudong Hang; Xueqing Jiang; Liping Zeng; Jia Jia; Yong Xie; Fei Li; Hongkai Bi
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 3.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

Review 4.  The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment.

Authors:  Rahul Shinde; Tracy L McGaha
Journal:  Trends Immunol       Date:  2018-11-05       Impact factor: 16.687

Review 5.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

6.  Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer.

Authors:  Aparna Mitra; Greyson Willis Grossman Biegert; Andrea Y Delgado; Tatiana V Karpinets; Travis N Solley; Melissa P Mezzari; Kyoko Yoshida-Court; Joe F Petrosino; Megan D Mikkelson; Lilie Lin; Patricia Eifel; Jianhua Zhang; Lois M Ramondetta; Anuja Jhingran; Travis T Sims; Kathleen Schmeler; Pablo Okhuysen; Lauren E Colbert; Ann H Klopp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-25       Impact factor: 7.038

Review 7.  Gut Microbiome Modulates Response to Cancer Immunotherapy.

Authors:  Md Abdul Wadud Khan; Gabriel Ologun; Reetakshi Arora; Jennifer L McQuade; Jennifer A Wargo
Journal:  Dig Dis Sci       Date:  2020-03       Impact factor: 3.199

8.  Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations.

Authors:  Ching-Hsuan Chen; Yen-Shen Lu; Ann-Lii Cheng; Chiun-Sheng Huang; Wen-Hung Kuo; Ming-Yang Wang; Ming Chao; I-Chun Chen; Chun-Wei Kuo; Tzu-Pin Lu; Ching-Hung Lin
Journal:  Oncologist       Date:  2019-08-01

Review 9.  Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.

Authors:  Connie Kang; Yahiya Y Syed
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.